Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression

Journal of Pharmacology and Experimental Therapeutics

Volumn 348, Issue 3, 2014, Pages 452-458

  Clarke, John D ^a   Hardwick, Rhiannon N ^a   Lake, April D ^a   Canet, Mark J ^a   Cherrington, Nathan J ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C11; CYTOCHROME P450 3A; SIMVASTATIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DOWN REGULATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG UPTAKE; MALE; MOUSE; MYOPATHY; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR;

ANIMALS; DOWN-REGULATION; FATTY LIVER; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; MALE; ORGANIC ANION TRANSPORTERS; RATS; RATS, SPRAGUE-DAWLEY; SIMVASTATIN;

EID: 84896728265     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.211284     Document Type: Article

References (44)

1. Abel T, Fehér J, Dinya E, Eldin MG, and Kovács A (2009) Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease. Med Sci Monit 15:MS6-MS11.
2. Ali R and Cusi K (2009) New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Ann Med 41:265-278.
3. Bruckert E, Hayem G, Dejager S, Yau C, and Bégaud B (2005) Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients- the PRIMO study. Cardiovasc Drugs Ther 19:403-414.
4. Canet MJ, Hardwick RN, Lake AD, Kopplin MJ, Scheffer GL, Klimecki WT, Gandolfi AJ, and Cherrington NJ (2012) Altered arsenic disposition in experimental nonalcoholic fatty liver disease. Drug Metab Dispos 40:1817-1824.
5. Chen C, Stock JL, Liu X, Shi J, Van Deusen JW, DiMattia DA, Dullea RG, and de Morais SM (2008) Utility of a novel Oatp1b2 knockout mouse model for evaluating the role of Oatp1b2 in the hepatic uptake of model compounds. Drug Metab Dispos 36:1840-1845.
6. Clarke JD and Cherrington NJ (2012) Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions. Expert Opin Drug Metab Toxicol 8:349-360.
7. DeGorter MK, Urquhart BL, Gradhand U, Tirona RG, and Kim RB (2012) Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/-mice and intraindividual variability in human subjects. J Clin Pharmacol 52:1689-1697.
8. Delcò F, Tchambaz L, Schlienger R, Drewe J, and Krähenbühl S (2005) Dose adjustment in patients with liver disease. Drug Saf 28:529-545.
9. Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, and Kechagias S (2006) Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44:865-873.
10. Elsby R, Hilgendorf C, and Fenner K (2012) Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1. Clin Pharmacol Ther 92:584-598.
11. Fan JG (2008) Impact of non-alcoholic fatty liver disease on accelerated metabolic complications. J Dig Dis 9:63-67.
12. Fernandez G, Spatz ES, Jablecki C, and Phillips PS (2011) Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med 78:393-403.
13. Fisher CD, Lickteig AJ, Augustine LM, Oude Elferink RP, Besselsen DG, Erickson RP, and Cherrington NJ (2009) Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats. Eur J Pharmacol 613:119-127.
14. Gandhi A, Moorthy B, and Ghose R (2012) Drug disposition in pathophysiological conditions. Curr Drug Metab 13:1327-1344.
15. Hardwick RN, Fisher CD, Canet MJ, Scheffer GL, and Cherrington NJ (2011) Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease. Drug Metab Dispos 39:2395-2402.
16. Hardwick RN, Fisher CD, Street SM, Canet MJ, and Cherrington NJ (2012) Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis. Drug Metab Dispos 40:450-460.
17. Ishigami M, Kawabata K, Takasaki W, Ikeda T, Komai T, Ito K, and Sugiyama Y (2001) Drug interaction between simvastatin and itraconazole in male and female rats. Drug Metab Dispos 29:1068-1072.
18. Iusuf D, Sparidans RW, van Esch A, Hobbs M, Kenworthy KE, van de Steeg E, Wagenaar E, Beijnen JH, and Schinkel AH (2012) Organic anion-transporting polypeptides 1a/1b control the hepatic uptake of pravastatin in mice. Mol Pharm 9: 2497-2504.
19. Kalliokoski A and Niemi M (2009) Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 158:693-705.
20. Lake AD, Novak P, Fisher CD, Jackson JP, Hardwick RN, Billheimer DD, Klimecki WT, and Cherrington NJ (2011) Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos 39:1954-1960.
21. Lickteig AJ, Fisher CD, Augustine LM, Aleksunes LM, Besselsen DG, Slitt AL, Manautou JE, and Cherrington NJ (2007) Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease. Drug Metab Dispos 35:1970-1978.
22. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, and Collins R; SEARCH Collaborative Group (2008) SLCO1B1 variants and statininduced myopathy-a genomewide study. N Engl J Med 359:789-799.
23. McCullough AJ (2006) Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 40 (Suppl 1):S17-S29.
24. Merrell MD and Cherrington NJ (2011) Drug metabolism alterations in nonalcoholic fatty liver disease. Drug Metab Rev 43:317-334.
25. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, Sterling RK, Shiffman ML, Stravitz RT, and Sanyal AJ (2003) Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 37:1286-1292.
26. Naik A, Belic A, Zanger UM, and Rozman D (2013) Molecular interactions between NAFLD and xenobiotic metabolism. Front Genet 4:2.
27. Nelson A, Torres DM, Morgan AE, Fincke C, and Harrison SA (2009) A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial. J Clin Gastroenterol 43:990-994.
28. Neuvonen PJ, Niemi M, and Backman JT (2006) Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 80:565-581.
29. Niemi M (2010) Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther 87:130-133.
30. Nseir W, Mograbi J, and Ghali M (2012) Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies. Dig Dis Sci 57:1773-1781.
31. Pasanen MK, Neuvonen M, Neuvonen PJ, and Niemi M (2006) SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 16:873-879.
32. Prueksaritanont T, Gorham LM, Ma B, Liu L, Yu X, Zhao JJ, Slaughter DE, Arison BH, and Vyas KP (1997) In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 25:1191-1199.
33. Prueksaritanont T, Qiu Y, Mu L, Michel K, Brunner J, Richards KM, and Lin JH (2005) Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. Pharm Res 22:1101-1109.
34. Shitara Y and Sugiyama Y (2006) Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 112:71-105.
35. Targher G, Bertolini L, Padovani R, Poli F, Scala L, Tessari R, Zenari L, and Falezza G (2006) Increased prevalence of cardiovascular disease in Type 2 diabetic patients with non-alcoholic fatty liver disease. Diabet Med 23:403-409.
36. Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R, Zenari L, and Falezza G (2005) Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 54:3541-3546.
37. Targher G, Bertolini L, Rodella S, Tessari R, Zenari L, Lippi G, and Arcaro G (2007) Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 30:2119-2121.
38. Thompson PD, Clarkson PM, and Rosenson RS; National Lipid Association Statin Safety Task Force Muscle Safety Expert Panel (2006) An assessment of statin safety by muscle experts. Am J Cardiol 97 (8A):69C-76C.
39. Verbeeck RK (2008) Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 64:1147-1161.
40. Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, and Ginsburg GS (2009) The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 54:1609-1616.
41. Watson RG and McLeod HL (2011) Pharmacogenomic contribution to drug response. Cancer J 17:80-88.
42. Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, Krauss RM, Roden DM, Feng Q, and Cooper-Dehoff RM, et al.; Clinical Pharmacogenomics Implementation Consortium (CPIC) (2012) The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatininduced myopathy. Clin Pharmacol Ther 92:112-117.
43. Yang AY, Sun L, Musson DG, and Zhao JJ (2005) Application of a novel ultra-low elution volume 96-well solid-phase extraction method to the LC/MS/MS determination of simvastatin and simvastatin acid in human plasma. J Pharm Biomed Anal 38:521-527.
44. Zaher H, Meyer zu Schwabedissen HE, Tirona RG, Cox ML, Obert LA, Agrawal N, Palandra J, Stock JL, Kim RB, and Ware JA (2008) Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin. Mol Pharmacol 74:320-329.